Loading
A phase 1/2 trial of Prednisone, Dexamethasone and Lenvatinib in advanced solid tumours, run by Eisai Inc., now recruiting.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types is a phase 1/2 interventional study registered as NCT04300556 by Eisai Inc., with 182 participants planned, started 2020-08-06 and due to reach its primary completion in 2030-08-08. Interventions recorded: Farletuzumab ecteribulin, Prednisone, Prednisolone, Dexamethasone and Lenvatinib.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Eisai, Lenvatinib and the tag pipeline.
Shares Eisai, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lenvatinib, Dexamethasone and the tag pipeline.
Shares Eisai, Lenvatinib and the tag pipeline.
Shares Lenvatinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Prednisone, Dexamethasone and the tag pipeline.
Shares Lenvatinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Lenvatinib, Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/